rtki cpd has been researched along with vatalanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
| Bondesson, M; Hans, C; Harris, PS; Hemmer, MJ; Kleinstreuer, N; Knudsen, TB; McCollum, CW; Merchant, FA; Olin, J; Padilla, S; Shah, S; Tal, TL; Wood, CE | 1 |
2 other study(ies) available for rtki cpd and vatalanib
| Article | Year |
|---|---|
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Immediate and long-term consequences of vascular toxicity during zebrafish development.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Blood Vessels; Embryo, Nonmammalian; Embryonic Development; ErbB Receptors; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2014 |